$Unicycive Therapeutics(UNCY.US$ has until January 6, 2025 to get its closing share price above $1.00 for 10 consecutive days or will face desliting on the NASDAQ CM. the company has also fallen below the $35 million minimum market value and has until January 7, 2025 to get its market value above $35 million for 10 consecutive days or the company will face delisting. The company plans to get its market value above the minimum level in the short term. The company may ei...
$Unicycive Therapeutics(UNCY.US$ Robert Leboyer of Noble Financial reiterated a Buy rating on Unicycive Therapeutics today, with a price target of $6.00.
1
$Unicycive Therapeutics(UNCY.US$ has finalized an order for the manufacture of OLC tablets to be completed and delivered by June 30, 2025. Another tranch of tablets will be ordered and delivered sometime between December 31, 2025 and June 30, 2026.
$Unicycive Therapeutics(UNCY.US$ This big drop is partially due to a reverse stock split that is coming soon. The stock price has closed below $1.00 since May 23rd. Despite the good news on the drug trials, Unicycive will need to raise the stock price in order to remain listed on the NasdaqCM…and this means a reverse stock split. Investors on trading platforms like Morgan Stanley, E*Trade, and TD Ameritrade are probably dumping their shares to avoid a $38.00 reorgani...
2
$Unicycive Therapeutics(UNCY.US$ Maxim Group analyst Jason McCarthy maintained a Buy rating on Unicycive Therapeutics) yesterday and set a price target of $4.00.
2
$Unicycive Therapeutics(UNCY.US$ HC Wainwright & Co reiterated Buy rating and maintained $4.50 price target.
$Unicycive Therapeutics(UNCY.US$ Unicycive Therapeutics Achieves Study Objectives in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial
LOS ALTOS, Calif., June 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced positive results from the Oxylanthanum Carbonate (OLC) UNI-OLC-201 pivotal clinical trial with regard to both safety and to...
LOS ALTOS, Calif., June 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced positive results from the Oxylanthanum Carbonate (OLC) UNI-OLC-201 pivotal clinical trial with regard to both safety and to...